| 0.9302 -0.045 (-4.64%) | 02-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.33 |
1-year : | 1.69 |
| Resists | First : | 1.14 |
Second : | 1.45 |
| Pivot price | 0.89 |
|||
| Supports | First : | 0.64 |
Second : | 0.54 |
| MAs | MA(5) : | 0.95 |
MA(20) : | 0.87 |
| MA(100) : | 0.73 |
MA(250) : | 1.04 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 37.5 |
D(3) : | 36.7 |
| RSI | RSI(14): 54.5 |
|||
| 52-week | High : | 1.78 | Low : | 0.55 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CYTH ] has closed below upper band by 44.7%. Bollinger Bands are 234.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1 - 1.01 | 1.01 - 1.01 |
| Low: | 0.84 - 0.84 | 0.84 - 0.85 |
| Close: | 0.92 - 0.93 | 0.93 - 0.94 |
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
Sun, 09 Feb 2025
Cyclo Therapeutics reports promising NPC1 treatment findings - MSN
Fri, 07 Feb 2025
Breakthrough NPC1 Treatment Data: 87% of Young Patients Show Recovery Signs in Cyclo Trial - StockTitan
Tue, 28 Jan 2025
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates WMPN, ALVR, CYTH on Behalf of Shareholders - Finansavisen
Wed, 22 Jan 2025
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger - CYTH, ALVR, WMPN, OMC - Finansavisen
Tue, 14 Jan 2025
Cyclo Therapeutics to Present Groundbreaking Trappsol® Cyclo™ Research at WORLDSymposium 2025 - StockTitan
Thu, 14 Nov 2024
Cyclo Therapeutics Completes Phase 3 Trial Enrollment, Plans 2025 NDA Filing Amid Merger - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 33 (M) |
| Held by Insiders | 1.161e+007 (%) |
| Held by Institutions | 47.5 (%) |
| Shares Short | 119 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.467e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 545.9 % |
| Return on Equity (ttm) | -284.3 % |
| Qtrly Rev. Growth | 870730 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.03 |
| EBITDA (p.s.) | -0.68 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 27.94 |
| Price to Cash Flow | 0.96 |
| Dividend | 0 |
| Forward Dividend | 131000 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|